RAAS Inhibitor Drugs in Dialysis Patients

University of Campania Luigi Vanvitelli350 enrolled

Overview

Hypertensive haemodialysis patients are at high risk for cardiovascular events. This study was undertaken to ascertain whether the upstream of aliskirne, a direct renin inhibitor improves mortality and cardiovascular outcomes in these high-risk population.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

350

Conditions

Hypertension End Stage Renal Disease

Interventions

aliskirenDRUG

150 mg once a day per 2 week with forced uptitration to 300 mg once a day, if tolerated

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * chronic kidney disease stage 5 * undergoing maintenance haemodialysis for a minimum of 3 months * existing arterial hypertension or * history of arterial hypertension or * resting blood pressure ≥140/90 mmHg or * antihypertensive medication * man and female * 18 years and older. Exclusion Criteria: * recent myocardial infarction (less than 3 months) * atrial fibrillation/atrial flutter * hypotension with systolic blood pressure of \<90 mmHg * high-grade aortic stenosis * left ventricular ejection fration \<50% * known allergy to aliskiren * severe disorders of liver function

Outcomes

Primary Outcomes

time to first clinical event (among mortality from any cause, cardiac event including myocardial infarction, need for coronary angioplasty or coronary bypass surgery, ischaemic stroke, new-onset heart failure, new-onset atrial fibrillation)

Time frame: 30 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.